CURE FOR IBD INC (EIN 471144322) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2015

Legal Domicile

Principal Officer

CHRISTOPHER PEDICONE

Phone

7326275062

Tax Period

2023-01-01 to 2023-12-31

CURE FOR IBD INC, founded in 2015, is a micro nonprofit in the Diseases & Disorders sector that reported $48K in total revenue in fiscal year 2023. Revenue fell 54% from the prior year — a significant decline worth monitoring. Expenses of $89K exceeded revenue, resulting in a 88% operating deficit.

Mission

TO FUND RESEARCH TOWARD NEW TREATMENTS AND CURES FOR CROHN'S DISEASE AND ULCERATIVE COLITIS; TO RAISE GLOBAL AWARENESS OF INFLAMMATORY BOWEL DISEASE BY EMPOWERING THE IBD COMMUNITY.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $47,586

Program Service Revenue $0

Investment Income $54

Other Revenue $0

TOTAL REVENUE $47,640

Expense Breakdown

Grants Paid $70,000

Salaries & Benefits $0

Fundraising Expenses $272

Program Expenses $70,000

Other Expenses $19,368

TOTAL EXPENSES $89,368

Year-over-Year Comparison

	2023	2022	Change
Revenue	$47,640	$103,462	-0.5%
Expenses	$89,368	$76,938	+0.2%
Net Income	$-41,728	$26,524	-2.6%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
CHRISTOPHER PEDICONE	TREASURER	10.00	Officer Director	$0	$0	$0
TRACEY MEYER	VICE PRESIDENT	4.00	Officer Director	$0	$0	$0
JENNIFER LITTLE	TRUSTEE	0.50	Director	$0	$0	$0
PATRICIA KAUFMAN	PRESIDENT & SECRETARY	10.00	Officer Director	$0	$0	$0
THOMAS PLAZA	TRUSTEE	0.50	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2023	$47,640	$89,368	$89,537	$-41,728
2022	$103,462	$76,938	$131,265	$26,524
2021	$178,562	$158,063	$104,741	$20,499
2020	$199,382	$224,699	$84,559	$-25,317
2019	$337,018	$453,689	$111,570	$-116,671
2018	$786,187	$754,505	$226,230	$31,682
2018	$803,532	$754,507	$206,848	$49,025

CURE FOR IBD INC